Because MICA/B is a regulator of antitumor immunity1–3 and the FAAH-mediated pathway is under evaluation as a target for neurological conditions, for example, post-traumatic stress disorder44,45, application of FAAH inhibitors in the cancer therapeutic field as a drug repositioning strategy may be a practical method to enhance anti-tumor immunotherapy. The gene discussed is FAAH; the disease is neoplasm.